Table 4.
Comparison of results of the present study with previous studies
| Characteristic | Present study | Kumar et al. [6] | Malhotra et al. [7] | Gokarn et al. [8] |
|---|---|---|---|---|
| N | 245 | 225 | 94 | 85 |
| Median age (years) | 51 | 53 | 53 | 49 |
| Males (%) | 69 | 69 | 73.7 | NR |
| Use of novel agents (%) | 52.5 | 56.9 | > 80 | > 75 |
| Median time to transplant (in months) | 10.5 | 10 | 10.5 | 10.5 |
| Pretransplant CR+VGPR (%) | 56 | 44 | 81 | 72 |
| Posttransplant CR+VGPR (%) | 83 | 74 | NR | 73 |
| TRM (%) | 2.86 | 7.2 | 3.19 | NR |
| OS | 5 year–61.6 ± 3.8% | 5 year–63.2% | 76.7% at 6.5 years | 3 year–91% |
| PFS | 5 year–37.2 ± 3.9% | 5 year–38.5% | 55.8% at 6.5 years | 3 year–58% |
| Factors associated with OS/PFS | Pre-ASCTR; Post-ASCTR; M; | Post-ASCTR; Alb; extramedullary disease; ISS; Chemo; ALC; DSS | NR | Pre-ASCTR; extramedullary disease; negative PET-CT pre-transplant |
N number of patients, Pre-ASCTR remission status pretransplant, Post-ASCTR remission status post-transplant, Chemo number of lines of pretransplant chemotherapies, M maintenance therapy, Alb serum albumin, ISS ISS stage, DSS Durie–Salmon stage, ALC absolute lymphocyte count at diagnosis, NR not reported